Anlong Bio is a leading gene therapy company focused on developing targeted treatments for rare diseases with significant clinical needs, both in China and globally. The company has established a robust platform utilizing adeno-associated virus (AAV) and RNA interference (RNAi) technologies, which are pivotal in their gene therapy development efforts. Anlong Bio aims to provide innovative, accessible, and affordable treatments by leveraging its extensive resources, experienced leadership, and a reliable network of partners. Their commitment to collaboration, agility, foresight, and innovation underpins their mission to expedite the delivery of transformative gene therapies to patients worldwide.

The company has made significant strides since its founding in 2019, including raising substantial funding to support its clinical and manufacturing capabilities. Anlong Bio has initiated multiple preclinical projects and has successfully advanced its AAV gene therapy product, AL-001, which targets age-related macular degeneration. Their focus on scalable manufacturing and high-quality research, combined with a strong team of global experts, positions Anlong Bio as a key player in the gene medicine landscape. Through collaborations with public sectors, industry, and academia, the company aims to make a meaningful impact in the field of healthcare and rare disease treatment.

China

At Anlong Bio, patients are our priority. Since launching, our goal has been to deliver transformative gene therapy medicines to patients faster and at low cost, in China and globally.

We aim to provide unmatched access to treatments for patients through our extensive resources, our experienced leadership and advisory teams, and our trusted network of partners.


Anlong Bio

Company Details